Takeda has acquired Nimbus Lakshmi, Inc., from Nimbus Therapeutics. Under terms of the agreement, and upon approval from the Federal Trade Commission (FTC), Takeda will acquire 100% Ownership of Nimbus Therapeutics’ TYK2 Program Subsidiary. Takeda will pay Nimbus approximately $ 4 billion upfront, after adjusting items including closing indebtedness and closing account payable of Lakshmi. Takeda will also make two milestone payments to Nimbus of $1 billion each upon achieving annual net...